Volume | 1,387,153 |
|
|||||
News | - | ||||||
Day High | 11.80 | Low High |
|||||
Day Low | 11.53 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Dynavax Technologies Corp | DVAX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
11.73 | 11.53 | 11.80 | 11.64 | 11.74 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
14,767 | 1,387,153 | $ 11.64 | $ 16,153,196 | - | 10.57 - 15.15 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:52:00 | 8 | $ 11.51 | USD |
Dynavax Technologies Corp Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.52B | 130.61M | - | 232.28M | -6.39M | -0.05 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Dynavax Technologies News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DVAX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 11.28 | 12.065 | 11.24 | 11.60 | 1,717,614 | 0.36 | 3.19% |
1 Month | 12.03 | 12.11 | 11.03 | 11.66 | 2,155,107 | -0.39 | -3.24% |
3 Months | 12.83 | 13.265 | 11.03 | 12.15 | 1,993,391 | -1.19 | -9.28% |
6 Months | 14.41 | 15.01 | 11.03 | 12.91 | 1,881,827 | -2.77 | -19.22% |
1 Year | 11.24 | 15.15 | 10.57 | 13.21 | 1,760,566 | 0.40 | 3.56% |
3 Years | 8.79 | 21.39 | 7.09 | 12.98 | 2,179,417 | 2.85 | 32.42% |
5 Years | 6.86 | 21.39 | 1.80 | 9.83 | 2,628,947 | 4.78 | 69.68% |
Dynavax Technologies Description
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of hepatitis B. Dynavax operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product. |